[go: up one dir, main page]

WO2005115304A3 - Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie - Google Patents

Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie Download PDF

Info

Publication number
WO2005115304A3
WO2005115304A3 PCT/IB2005/001371 IB2005001371W WO2005115304A3 WO 2005115304 A3 WO2005115304 A3 WO 2005115304A3 IB 2005001371 W IB2005001371 W IB 2005001371W WO 2005115304 A3 WO2005115304 A3 WO 2005115304A3
Authority
WO
WIPO (PCT)
Prior art keywords
kit inhibitors
fibrodysplasia
treating
treating fibrodysplasia
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/001371
Other languages
English (en)
Other versions
WO2005115304A2 (fr
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
AB Science SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AB Science SA filed Critical AB Science SA
Publication of WO2005115304A2 publication Critical patent/WO2005115304A2/fr
Publication of WO2005115304A3 publication Critical patent/WO2005115304A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé qui permet de traiter la fibrodysplasie telle que la fibrodysplasie ossifiante progressive, selon lequel on administre un composé capable de dépléter les mastocytes ou un composé inhibant la dégranulation des mastocytes à un humain qui en a besoin. Les composés tels que le composé précité peuvent être choisis parmi des inhibiteurs de c-kit et, en particulier, parmi des inhibiteurs de c-kit puissants, sélectifs et non toxiques. De préférence, l'inhibiteur n'est pas capable de promouvoir la mort des cellules dépendantes de l'IL-3 cultivées en présence d'IL-3.
PCT/IB2005/001371 2004-05-24 2005-04-19 Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie Ceased WO2005115304A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57334504P 2004-05-24 2004-05-24
US60/573,345 2004-05-24

Publications (2)

Publication Number Publication Date
WO2005115304A2 WO2005115304A2 (fr) 2005-12-08
WO2005115304A3 true WO2005115304A3 (fr) 2006-04-06

Family

ID=35276073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001371 Ceased WO2005115304A2 (fr) 2004-05-24 2005-04-19 Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie

Country Status (1)

Country Link
WO (1) WO2005115304A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2358A (en) 2005-05-09 2012-01-30 Achillion Pharmaceuticals Inc Thiazole compounds and methods of use.
EP3960764A1 (fr) 2006-11-03 2022-03-02 The Board of Trustees of the Leland Stanford Junior University Immunodéplétion sélective de niche de cellules souches endogènes pour greffe
BRPI0811939A2 (pt) 2007-05-22 2014-11-25 Achillion Pharmaceuticals Inc Tiazóis substituídos por heteroarila
US20110105436A1 (en) * 2008-03-10 2011-05-05 Auckland Uniservices Limited Heteroaryl compounds, compositions, and methods of use in cancer treatment
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
US8344018B2 (en) 2008-07-14 2013-01-01 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
AU2009271003A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolylpyrimidine compounds as HDAC and/or CDK inhibitors
WO2010009155A2 (fr) 2008-07-14 2010-01-21 Gilead Colorado, Inc. Composés inhibiteurs hétérocycliques condensés
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
CA2763786C (fr) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Composes inhibiteurs d'hdac a base d'alkanoylamino benzamide aniline
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
US9789074B2 (en) 2010-09-01 2017-10-17 Thomas Jefferson University Composition and method for muscle repair and regeneration
EP2970196B1 (fr) 2013-03-15 2020-11-25 Global Blood Therapeutics, Inc. Composés et leurs utilisations pour la modulation de l'hémoglobine
EA202092627A1 (ru) 2013-11-18 2021-09-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2017210792A1 (fr) 2016-06-08 2017-12-14 Clementia Pharmaceuticals Inc. Méthodes pour le traitement de l'ossification hétérotopique
EA039050B1 (ru) 2016-11-16 2021-11-26 Клементиа Фармасьютикалс Инк. Способы лечения множественного остеохондроматоза (мо)
EP3675878A4 (fr) 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center Agents de liaison aux récepteurs de l'hormone lutéinisante et agonistes de l'hormone lutéinisante utilisés pour identifier, multiplier, retirer et modifier des populations de cellules souches primitives
JP7663603B2 (ja) 2020-04-24 2025-04-16 バイエル・アクチエンゲゼルシヤフト 免疫活性化のためのｄｇｋｚｅｔａ阻害剤としての置換アミノチアゾール類

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010391A1 (fr) * 1998-08-25 2000-03-02 Medco Research, Inc. Utilisation d'antagonistes de recepteurs d'adenosine a3 pour inhiber la croissance tumorale
WO2002045652A2 (fr) * 2000-12-04 2002-06-13 Merck & Co., Inc. Inhibiteurs de tyrosine-kinase
WO2002053101A2 (fr) * 2000-12-29 2002-07-11 Alteon, Inc. Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2002094842A2 (fr) * 2001-05-24 2002-11-28 University Of Western Ontario Regulation de la myogenese par modulation de l'activite de la proteine-kinase p38 associee aux membranes
WO2003002109A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines a traiter des maladies auto-immunes
WO2004014903A1 (fr) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010391A1 (fr) * 1998-08-25 2000-03-02 Medco Research, Inc. Utilisation d'antagonistes de recepteurs d'adenosine a3 pour inhiber la croissance tumorale
WO2002045652A2 (fr) * 2000-12-04 2002-06-13 Merck & Co., Inc. Inhibiteurs de tyrosine-kinase
WO2002053101A2 (fr) * 2000-12-29 2002-07-11 Alteon, Inc. Procede de traitement de troubles fibrogenes et autres symptomes de type ivc
WO2002094842A2 (fr) * 2001-05-24 2002-11-28 University Of Western Ontario Regulation de la myogenese par modulation de l'activite de la proteine-kinase p38 associee aux membranes
WO2003002109A2 (fr) * 2001-06-29 2003-01-09 Ab Science Utilisation d'inhibiteurs de tyrosine kinase destines a traiter des maladies auto-immunes
WO2004014903A1 (fr) * 2002-08-02 2004-02-19 Ab Science 2-(3-aminoaryl)amino-4-aryl-thiazoles et leur utilisation en tant que inhibiteurs de c-kit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GANNON FRANCIS H ET AL: "Mast cell involvement in fibrodysplasia ossificans progressiva", HUMAN PATHOLOGY, vol. 32, no. 8, August 2001 (2001-08-01), pages 842 - 848, XP002354246, ISSN: 0046-8177 *
JOB-DESLANDRE CHANTAL: "Inherited ossifying diseases.", JOINT, BONE, SPINE : REVUE DU RHUMATISME. MAR 2004, vol. 71, no. 2, March 2004 (2004-03-01), pages 98 - 101, XP002354247, ISSN: 1297-319X *

Also Published As

Publication number Publication date
WO2005115304A2 (fr) 2005-12-08

Similar Documents

Publication Publication Date Title
WO2005115304A3 (fr) Utilisation d'inhibiteurs de c-kit pour le traitement de la fibrodysplasie
WO2005016323A3 (fr) Utilisation d'inhibiteurs de c-kit pour le traitement du diabete de type ii
GEP20125537B (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
SG179418A1 (en) Inhibitors of the hedgehog pathway
WO2008033562A3 (fr) Composés inhibiteurs de kinases
MX2009006535A (es) Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
WO2005117867A3 (fr) Heterocycles monocycliques commes inhibiteurs de kinases
MX2013004491A (es) Boronatos como inhibidores de arginasa.
WO2010021680A3 (fr) Inhibiteurs de la bêta-sécrétase
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
ZA200902384B (en) Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
WO2003028711A3 (fr) Utilisation d'inhibiteurs de c-kit pour traiter un myelome
MX2012000766A (es) Compuestos triazolopiridina, y su accion como inhibidor de prolil hidroxilasa e inductor de la produccion de eritropoyetina.
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
UA106054C2 (uk) ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ
WO2009140621A8 (fr) Compositions et procédés ayant trait aux composés activant le facteur de transcription de choc thermique et cibles correspondantes
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
WO2007133865A3 (fr) Composés organiques et leurs utilisations
WO2003024386A8 (fr) Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse
MY162022A (en) Chemical compounds 637: pyridopyrimidinediones as pde4 inhibitors
WO2005102346A3 (fr) Utilisation des inhibiteurs de c-kit pour le traitement de la fibrose
MX2009006256A (es) Composiciones intensificadoras inhibidoras de corrosion y metodos relacionados.
WO2007026251A3 (fr) Utilisation d'inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
WO2007111948A3 (fr) Inhibiteurs de prényltransférases protéiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase